Anti-LBPA Antibody, clone 6C4 ZooMAb® Mouse Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone C64 is a ZooMAb® mouse recombinant monoclonal antibody that detects lyso(bis)phosphatidic acid (LBPA).
• Immunogen: Endosomal membranes from baby hamster kidney fibroblasts (BHK).
• Application: Quality Control TestingEvaluated by Immunocytochemistry in NIH3T3 cells.Immunocytochemistry Analysis: A 1:100 dilution of this antibody detected LBPA in NIH3T3.Tested applicationsImmunocytochemistry Analysis: A 1:100 dilution from a representative lot detected LBPA in A549 and HeLa cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected LBPA in a Formalin Fixed Paraffin Embedded section of a pellet of HeLa cells stimulated with 10 M thioperamide (72 h).Enzyme Immunoassay Analysis: A representative lot of this antibody detected LBPA in ELISA application.Affinity Binding Assay: A representative lot of this antibody bound LBPA with a KD of 6.5 x 10-6 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
• Target description: Lyso(bis)phosphatidic acid (LBPA) is a structural isomer of phosphatidylglyerol with an atypical phospholipid stereo configuration. It is found in all animal tissues in a small amount ( 1%). However, it is only detected in late endosomes where it accounts for up to 17 mol % of total membrane phospholipids. It is abundant in the intralumenal vesicles that accumulate within late endosomes, accounting for the characteristic multi-vesicular appearance of these organelles. Late endosomes function not only as a major protein-sorting compartment, but also an obligatory station for LDL and other endocytosed ligands destined for degradation. LBPA is involved in the traffic of proteins and lipids that transit via late endosomes where membranes rich in LBPA regulate cholesterol transport and assist in presenting sphingolipids to their degradation enzymes. LBPA is shown to be highly resistant to lipases and phospholipases. Niemann Pick Type C (NPC) disease, caused by a mutation in either Niemann Pick C1 or C2 protein, results in lysosomal and endosomal disorders leading to excessive accumulation of cholesterol, particularly in skin fibroblasts. LBPA treatment of cells with NPC1 mutations is reported to compensate for the loss of NPC1 and reduce cholesterol build up and improve lysosomal function. However, LBPA is reported to be ineffective in reducing cholesterol build-up in NPC2 deficient cells. This ZooMAbZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Ilnytska, O., et al. (2021). J. Biol. Chem. 297(1); 100813; McCauliff, LA., et al. (2019). eLife. 8; e50832; Goursot, A., et al. (2010). J. Physiol. Chem. B. 114(47); 15712-15720).
• Physical form: Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.